Pharsight

Vyzulta generic

Vyzulta is an intraocular pressure reduction drug owned by Bausch And Lomb. It contains the active ingredient, latanoprostene bunod, and was first authorized for market use on 02 November, 2017. The drug comes in solution/drops; ophthalmic dosage forms.

When will Vyzulta generic be available?

The generic version of Vyzulta is expected to become available after 03 October, 2025. This is because the last patent protecting Vyzulta from generic competition expires on this date. The release of generic alternatives often follows the expiration of the last patent.

Vyzulta uses

Vyzulta is primarily used to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Its active ingredient, latanoprostene bunod, effectively controls eye pressure to prevent further damage to the patient's sight.

Vyzulta patent expiration

Vyzulta is protected by a total of 4 patents. The last of these, titled 'Prostaglandin derivatives,' expires on 03 October, 2025, after which the Vyzulta generic may emerge on the market. Below are the details of the patent:

EPO Oppostions filed on Vyzulta

Vyzulta dosage

Want to ask something?